Search Results

The Control Set DAT I is for use as an assayed control in the Roche test system for the qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers as indicated in the System Information.
The Control Set DAT II is for use as an assayed control in the Roche test system for the qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers as indicated in the System Information.
The Control Set DAT III is for use as an assayed control in the Roche test system for the qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers as indicated in the System Information.
The Control Set Amphetamine 1000 is for use as an assayed control with the Roche Abuscreen OnLine assay for Amphetamines and the COBAS INTEGRA Amphetamines cobas c pack (AMPS) for the qualitative and semiquantitative determination of amphetamines in human urine on automated clinical chemistry analyzers.
The Control Set Amphetamine 500 is for use as an assayed control with the Roche Abuscreen OnLine assay for Amphetamines and the COBAS INTEGRA Amphetamines cobas c pack (AMPS) for the qualitative and semiquantitative determination of amphetamines in human urine on automated clinical chemistry analyzers.

Control Set DAT I is prepared by the quantitative addition of drug or drug metabolite to drug-free human urine. Preservative and stabilizer are added to maintain product integrity. Control Set DAT I contains a mixture of 10 different drugs. Drug concentrations in are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at ± 25% of the assay cutoff.
Control Set DAT II is prepared by the quantitative addition of drug or drug metabolite to drug-free human urine. Preservative and stabilizer are added to maintain product integrity. Control Set DAT II contains a mixture of 4 different drugs. Drug concentrations in Control Set DAT II are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at ± 25% of the assay cutoff.
Control Set DAT III is prepared by the quantitative addition of drug or drug metabolite to drug-free human urine. Preservative and stabilizer are added to maintain product integrity. Control Set DAT III contains a mixture of 4 different drugs. Drug concentrations in Control Set DAT II are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at ± 25% of the assay cutoff.
Control Set Amphetamine 1000 is prepared by the quantitative addition of d-amphetamine to drug-free human urine. Preservative is added to maintain product integrity. Drug concentrations in Control Set Amphetamine 1000 are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at ± 25% of the assay cutoff.
Control Set Amphetamine 500 is prepared by the quantitative addition of d-amphetamine to drug-free human urine. Preservative is added to maintain product integrity. Drug concentrations in Control Set Amphetamine 500 are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at ± 25% of the assay cutoff.

The provided documentation describes the Control Set DAT I, II, III, Control Set Amphetamine 1000, and Control Set Amphetamine 500 products as "Drug Mixture Control Materials." These are controls used to verify the performance of drug abuse testing systems. The "study" described is primarily focused on characterizing the control materials themselves, not a clinical study involving the device's diagnostic performance on patient samples.

Therefore, many of the typical acceptance criteria and study design elements for AI/diagnostic devices will not be applicable here. This document describes the creation and verification of the control materials.

Here's an analysis based on the available information:

Acceptance Criteria and Reported Device Performance

The acceptance criteria for these control sets are primarily defined by their target concentrations for various drugs, established as ±25% of the assay cutoff. The "reported device performance" in this context refers to the verification of these target concentrations using Gas Chromatography/Mass Spectrometry (GC/MS).

Note: The document states that drug concentrations are verified by GC/MS, implying that these target concentrations were successfully achieved and confirmed. Specific numerical results of this verification (e.g., actual measured concentrations and their variances) are not provided in this summary, only the target ranges.

Study Details (as applicable)

1. Sample size used for the test set and the data provenance: This document describes the preparation and verification of control materials, not a study evaluating a diagnostic device with patient samples. Therefore, there isn't a "test set" in the traditional sense of patient data. The "samples" are the control materials themselves, which are prepared from "drug-free human urine" with quantitative additions of specific drugs/metabolites. The provenance of the drug-free human urine or the origin of drug substances is not specified. It's a laboratory-prepared product.

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable. The "ground truth" for the concentrations in the control materials is established by the quantitative addition of known amounts of drugs and then verified by GC/MS, an analytical chemistry technique. This does not involve human expert interpretation of a diagnostic outcome.

3. Adjudication method (e.g., 2+1, 3+1, none) for the test set: Not applicable. As this is not a diagnostic interpretation study, there is no adjudication process involving human experts.

4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. This document pertains to control materials for drug testing, not an AI-powered diagnostic device or a study involving human readers.

5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done: Not applicable. These are control materials, not an algorithm.

6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.): The "ground truth" for the control materials is the known, quantitatively added concentrations of specific drugs/metabolites, verified by an analytical method (Gas Chromatography/Mass Spectrometry (GC/MS)).

7. The sample size for the training set: Not applicable. Control materials do not have a "training set" in the context of machine learning or diagnostic algorithm development.

8. How the ground truth for the training set was established: Not applicable.

Ask a specific question about this device